HEMATOLOGIC ONCOLOGY--DRUG DEVELOPMENT AND TESTING

血液肿瘤学项目的总体目标是开发和测试 治疗血液肿瘤的新的有效策略， 剂量密集的方法和生物疗法。 具体目标是： 1.为了测试治疗非霍奇金淋巴瘤的新剂量密集策略， 淋巴瘤和骨髓瘤伴生长因子和干细胞支持，和 监测微小残留病（项目2-1、2-2、2-3）。 2.开发和测试慢性淋巴细胞性白血病的治愈性治疗， 白血病与微小残留病评估（项目2-3）。 3.为血液肿瘤开发新的生物疗法（项目2- 7）。 项目2-1的重点是克隆型PCR的开发和应用 用于监测微小残留病，项目2-2检查了 干细胞动员治疗复发性淋巴瘤的剂量密集方法。 项目2-3提出了一种治疗慢性淋巴细胞性白血病的治疗方案。 白血病微小残留病PCR检测 项目2-4 探讨了低风险急性髓细胞白血病的治疗方法 联合化疗与集落刺激因子 治疗 项目2-5研究新的化疗和分化 血液肿瘤学中的药物。 这些项目遵循总的主题 与实体肿瘤紧密结合 肿瘤学项目。

The overall aim of the Hematologic Oncology Project is to develop and test new and effective strategies for treating hematologic neoplasms using dose-intense approaches and biologic therapies. The Specific Aims are: 1. To test novel dose-intense strategies for treating non-Hodgkin's lymphoma and myeloma with growth factor and stem cell support, and monitoring of minimal residual disease (Projects 2-1, 2-2, 2-3). 2. To develop and test a curative intent treatment for chronic lymphocytic leukemia with assessment of minimal residual disease (Project 2-3). 3. To develop new biologic therapies for hematologic neoplasia (Project 2- 7). Project 2-1 focuses on the development and application of a clonotypic PCR for monitoring of minimal residual disease and Project 2-2 examines a dose-intense approach to relapsed lymphoma with stem cell mobilization. Project 2-3 proposes a curative intent protocol for chronic lymphocytic leukemia with PCR determination of minimal residual disease. Project 2-4 examines a therapeutic approach to poor-risk acute myelogenous leukemia integrating chemotherapy concomitant with colony-stimulating factor treatment. Project 2-5 examines new chemotherapeutic and differentiating agents in hematologic oncology. These projects follow the overall themes of the Program Project grant and integrate closely with the Solid Tumor Oncology Program.